UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): November 10, 2016
 
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-34637
 
20-1852016
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
 
25801 Industrial Boulevard, Suite B, Hayward,
California
 
94545
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (510) 856-5600
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
☐             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 8.01
Other Events.
 
On November 10, 2016, Anthera Pharmaceuticals, Inc. (the “Company”)  issued a press release announcing topline efficacy and safety data from the Company’s Phase 3 CHABLIS-SC1 clinical study with blisibimod for the treatment of systemic lupus erythematosus (SLE),  A copy of the press release is filed herewith as Exhibit 99.1.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Press Release, dated November 10, 2016
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 10, 2016
Anthera Pharmaceuticals, Inc.
 
 
 
 
 
By:
/s/ May Liu
 
 
May Liu
 
 
Senior Vice President, Finance and Administration
 
 
Exhibit Index

Exhibit No.
 
Description
 
 
 
99.1
 
Press Release, dated November 10, 2016
 
 
 
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Anthera Pharmaceuticals (CE) Charts.